364 related articles for article (PubMed ID: 35096390)
1. Tumor promoting roles of IL-10, TGF-β, IL-4, and IL-35: Its implications in cancer immunotherapy.
Mirlekar B
SAGE Open Med; 2022; 10():20503121211069012. PubMed ID: 35096390
[TBL] [Abstract][Full Text] [Related]
2. Saga of monokines in shaping tumour-immune microenvironment: Origin to execution.
Challagundla N; Shah D; Yadav S; Agrawal-Rajput R
Cytokine; 2022 Sep; 157():155948. PubMed ID: 35764025
[TBL] [Abstract][Full Text] [Related]
3. Immune-suppressive effects of interleukin-6 on T-cell-mediated anti-tumor immunity.
Tsukamoto H; Fujieda K; Senju S; Ikeda T; Oshiumi H; Nishimura Y
Cancer Sci; 2018 Mar; 109(3):523-530. PubMed ID: 29090850
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7.
Dubinett SM; Huang M; Dhanani S; Economou JS; Wang J; Lee P; Sharma S; Dougherty GJ; McBride WH
J Natl Cancer Inst; 1995 Apr; 87(8):593-7. PubMed ID: 7752257
[TBL] [Abstract][Full Text] [Related]
5. Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.
Valenti R; Huber V; Filipazzi P; Pilla L; Sovena G; Villa A; Corbelli A; Fais S; Parmiani G; Rivoltini L
Cancer Res; 2006 Sep; 66(18):9290-8. PubMed ID: 16982774
[TBL] [Abstract][Full Text] [Related]
6. Cancer Immunotherapy: Diverse Approaches and Obstacles.
Sanatkar SA; Heidari A; Rezaei N
Curr Pharm Des; 2022; 28(29):2387-2403. PubMed ID: 35909273
[TBL] [Abstract][Full Text] [Related]
7. Phenotypic profile of dendritic and T cells in the lymph node of Balb/C mice with breast cancer submitted to dendritic cells immunotherapy.
da Cunha A; Antoniazi Michelin M; Cândido Murta EF
Immunol Lett; 2016 Sep; 177():25-37. PubMed ID: 27423825
[TBL] [Abstract][Full Text] [Related]
8. Modulators affecting the immune dialogue between human immune and colon cancer cells.
Djaldetti M; Bessler H
World J Gastrointest Oncol; 2014 May; 6(5):129-38. PubMed ID: 24834143
[TBL] [Abstract][Full Text] [Related]
9. Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment.
Habanjar O; Bingula R; Decombat C; Diab-Assaf M; Caldefie-Chezet F; Delort L
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835413
[TBL] [Abstract][Full Text] [Related]
10. Signaling new therapeutic opportunities: cytokines in prostate cancer.
Chandran E; Meininger L; Karzai F; Madan RA
Expert Opin Biol Ther; 2022 Oct; 22(10):1233-1243. PubMed ID: 35930001
[TBL] [Abstract][Full Text] [Related]
11. IL-12 Family Cytokines in Cancer and Immunotherapy.
Mirlekar B; Pylayeva-Gupta Y
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33418929
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-κB and TGF-β signaling pathways.
Keklikoglou I; Koerner C; Schmidt C; Zhang JD; Heckmann D; Shavinskaya A; Allgayer H; Gückel B; Fehm T; Schneeweiss A; Sahin O; Wiemann S; Tschulena U
Oncogene; 2012 Sep; 31(37):4150-63. PubMed ID: 22158050
[TBL] [Abstract][Full Text] [Related]
13. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MC38 colon cancer growth by multicomponent chemoimmunotherapy with anti-IL-10R antibodies, HES-MTX nanoconjugate, depends on application of IL-12, IL-15 or IL-18 secreting dendritic cell vaccines.
Węgierek-Ciura K; Mierzejewska J; Szczygieł A; Rossowska J; Wróblewska A; Świtalska M; Goszczyński TM; Szermer-Olearnik B; Pajtasz-Piasecka E
Front Immunol; 2023; 14():1212606. PubMed ID: 37545526
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity.
Horn LA; Riskin J; Hempel HA; Fousek K; Lind H; Hamilton DH; McCampbell KK; Maeda DY; Zebala JA; Su Z; Schlom J; Palena C
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32188703
[TBL] [Abstract][Full Text] [Related]
16. Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor β on cancer cells.
Kwaśniak K; Czarnik-Kwaśniak J; Maziarz A; Aebisher D; Zielińska K; Karczmarek-Borowska B; Tabarkiewicz J
Cent Eur J Immunol; 2019; 44(2):190-200. PubMed ID: 31530989
[TBL] [Abstract][Full Text] [Related]
17. Transforming Growth Factor-β and Interleukin-10 Synergistically Regulate Humoral Immunity
Komai T; Inoue M; Okamura T; Morita K; Iwasaki Y; Sumitomo S; Shoda H; Yamamoto K; Fujio K
Front Immunol; 2018; 9():1364. PubMed ID: 29963056
[TBL] [Abstract][Full Text] [Related]
18. Lactic acid bacteria enhance autophagic ability of mononuclear phagocytes by increasing Th1 autophagy-promoting cytokine (IFN-gamma) and nitric oxide (NO) levels and reducing Th2 autophagy-restraining cytokines (IL-4 and IL-13) in response to Mycobacterium tuberculosis antigen.
Ghadimi D; de Vrese M; Heller KJ; Schrezenmeir J
Int Immunopharmacol; 2010 Jun; 10(6):694-706. PubMed ID: 20381647
[TBL] [Abstract][Full Text] [Related]
19. Control of CD4 effector fate: transforming growth factor beta 1 and interleukin 2 synergize to prevent apoptosis and promote effector expansion.
Zhang X; Giangreco L; Broome HE; Dargan CM; Swain SL
J Exp Med; 1995 Sep; 182(3):699-709. PubMed ID: 7650478
[TBL] [Abstract][Full Text] [Related]
20. Type 1 and type 2 cytokine-mediated immune orchestration in the tumour microenvironment and their therapeutic potential.
Jou E
Explor Target Antitumor Ther; 2023; 4(3):474-497. PubMed ID: 37455828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
